We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Futura Medical plc (FUM) Ordinary GBP0.02

Sell:31.90p Buy:32.00p 0 Change: 0.80p (2.44%)
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:31.90p
Buy:32.00p
Change: 0.80p (2.44%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:31.90p
Buy:32.00p
Change: 0.80p (2.44%)
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

Contact details

Address:
40 Occam Road
GUILDFORD
GU2 7YG
United Kingdom
Telephone:
+44 (01483) 685670
Website:
https://www.futuramedical.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 10 September 2024 10/09/24
AGM 20 June 2024 20/06/24
Annual report 24 May 2024 24/05/24
Final results 10 April 2024 10/04/24
Trading Announcement 06 February 2024 06/02/24

General stock information

EPIC:
FUM
ISIN:
GB0033278473
Market cap:
£96.88 million
Shares in issue:
303.70 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • James Barder
    Group Chief Executive, Executive Director
  • Angela Hildreth
    Finance Director, Chief Operating Officer, Company Secretary, Executive Director
  • Ken James
    Executive Director, Head of R&D

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.